stockrowAstraZeneca PLC
AZN Healthcare Drug Manufacturers General
AstraZeneca PLC’s revenue for fiscal 2025 (year ended December 2025) was $58.7 billion, up 8.63% from fiscal 2024.
- Revenue
- +6.70%
- EPS
- +22.5%
- Free cash flow
- +1.99%
- Total debt
- +1.75%
Quarter to September 2026, against a year earlier
Follow AZN
Alert me
AstraZeneca PLC (AZN) Operating cash flow
AstraZeneca PLC's operating cash flow for fiscal 2025 was $14.6B, up 22.9% from $11.9B in fiscal 2024. Over the twelve months to 30 September 2026 it was $13.2B. Over the past ten years it has ranged from $2.6B (fiscal 2018) to $14.6B (fiscal 2025) — the current reading is the highest in ten years. Operating cash flow has risen for 7 consecutive fiscal years. AstraZeneca PLC ranks 10th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $14.6B | 22.88% |
| FY2024 | $11.9B | 14.65% |
| FY2023 | $10.3B | 5.48% |
| FY2022 | $9.8B | 64.48% |
| FY2021 | $6.0B | 24.26% |
| FY2020 | $4.8B | 61.64% |
| FY2019 | $3.0B | 13.41% |
| FY2018 | $2.6B | (26.83%) |
| FY2017 | $3.6B | (13.68%) |
| FY2016 | $4.1B | 24.70% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Sep 2026 | $4.7B | 62.86% |
| Jun 2026 | $2.9B | (14.71%) |
| Mar 2026 | $3.4B | 43.42% |
| Dec 2025 | $2.3B | (54.38%) |
| 43 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| NVO Novo Nordisk A/S compare | $20.4B |
| ABBV AbbVie Inc. compare | $20.1B |
| MRK Merck & Co., Inc. compare | $20.0B |
| NVS Novartis AG compare | $17.3B |
| GILD Gilead Sciences, Inc. compare | $14.5B |
| PFE Pfizer Inc. compare | $14.2B |
| AZN AstraZeneca PLC | $13.2B |
| AMGN Amgen Inc. compare | $12.0B |
| BMY Bristol Myers Squibb Company compare | $10.7B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on AZN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement